Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Abstract

Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases. (Funded by Bristol-Myers Squibb and the National Cancer Institute; CheckMate 204 ClinicalTrials.gov number, NCT02320058 .).

Keywords

Affiliated Institutions

• Cleveland Clinic US
• University of Pittsburgh Medical Center US
• University of Colorado Cancer Center US
• Bristol-Myers Squibb (United States) US
• Stanford University US
• City Of Hope National Medical Center US
• Angeles Clinic and Research Institute US
• Georgetown Lombardi Comprehensive Cancer Center
• Moffitt Cancer Center US
• University of Colorado Denver US
• University of Michigan US
• Dana-Farber Cancer Institute US
• UNC Lineberger Comprehensive Cancer Center
• Emory University US
• Cancer Institute (WIA) IN
• New York University US
• The University of Texas MD Anderson Cancer Center US
• Cornell University US
• University of California, San Francisco US
• University of North Carolina at Chapel Hill US
• Memorial Sloan Kettering Cancer Center US
• Roswell Park Comprehensive Cancer Center US

Related Publications